Skip to main content

Gianna M. Nappi

Associate

[email protected]

+1.617.348.3055

Share:

Gianna focuses her practice on securities transactions, public and private offerings, corporate governance, and other general corporate matters. She works with public and private companies in a variety of industries, including life sciences and technology. Gianna has experience with representing clients in a variety of capital markets transactions, including initial public offerings, reverse mergers, follow-on offerings, and at-the-market offerings. She was a Summer Associate at Mintz in 2019.

While attending law school, Gianna was a legal intern at a Cambridge, Massachusetts-based biotechnology company that develops cancer immunotherapy treatments and a law clerk in Northeastern University’s Office of the General Counsel. She also served as an intern in Greater Boston Legal Services’ Elder, Health, and Disability Unit.

In law school, Gianna earned a JD with a concentration in Commercial and Business Law and served as an editorial board member of the Northeastern University Law Review, a student attorney at the Community Business Clinic, and a Legal Research and Writing teaching assistant. She was also chair of the Business Law Society, vice-chair of communications of the Student Bar Association, and internal-external relations chair of the Women’s Law Caucus.

News & Press

Press Release Thumbnail
CAMBRIDGE, Mass.—Mintz advised Quaise Energy, a developer of a new hybrid deep drilling technology for geothermal energy, in its recent $21 million Series A1 funding round. The deal brings Quaise’s total funding to more than $95 million. The investment will be used to scale up Quaise’s supply chain and enhance its field operations by improving geologic understanding at plant sites.
Press Release Thumbnail
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Read less

Recognition & Awards

  • Phi Beta Kappa

Read less